NICE Clinical Melanoma Guideline

NICE published the Clinical Melanoma Guideline in July 2015. This Guideline is directed at secondary and tertiary care (hospital treatment) in the UK and considers the role of treatments such as sentinel node biopsy.

This is a link to the guideline http://www.nice.org.uk/guidance/ng14

The Guideline addressed the role of sentinel node biopsy and regular body scans after diagnosis, among other  issues. The decision was made to develop information for melanoma patients about the advantages and disadvantages of sentinel node biopsy and regular imaging. This information was developed in conjunction with Option Grid and was published in December 2015. The grids can be obtained direct from the Option Grid web page but are also provided in the Option Grid post.

 

 

Vitamin D and melanoma: new podcast

NICE asked Professor Julia Newton-Bishop to discuss why vitamin D was considered by the Clinical Melanoma Guideline and this is the link to her podcast

 

New GenoMEL paper

The Journal of the National Cancer Institute has published a new GenoMEL paper examining the role of chromosomal telomere length in melanoma. The research involved creating a score representing genetically determined telomere length, based on all the established telomere associated genes and found that this score correlated with melanoma risk.

In an associated press release author Dr Mark Iles summarised the research, “Telomeres have been described as being like the plastic tips on shoelaces that protect the shoelace from fraying, just as telomeres protect chromosomes from degrading or fusing to one another. For the first time, we have established that the genes controlling the length of these telomeres play a part in the risk of developing melanoma.”

SHOE_LACES

Telomeres are akin to shoe lace caps (aglets)